Literature DB >> 3908586

[A clinico-pathological implication of ABO (H) blood group substances expressed in the primary lesion of uterine cervical carcinoma].

Y Sakamoto, M Kamada, Y Kishi, T Mori.   

Abstract

The disappearance of ABO(H) blood group antigens seen in the lesions of carcinoma of the uterine cervix has been studied by the Avidin-Biotin-Complex (ABC) method and the results have been correlated with histology and prognosis. The incidence of cases showing complete loss of A or B antigens was increased with progression in the pathological picture of cancer, whereas H antigen, known as precursor carbohydrate chains of A and B antigens, was still sustained even in most cases of invasive cancer. In the tissue of invasive cancer, the complete loss of H antigen was easily able to be demonstrated in the small cell non-keratinizing type of carcinoma, but it is hardly able to be seen in the large cell non-keratinizing type and not demonstrated in the keratinizing type of carcinoma. Though no relationship was recognized between the disappearance of A, B or H antigens and parametrial spread of carcinoma or metastasis to the pelvic lymphnodes, the incidence of patients who died within two years after operation was apparently higher in the H antigen negative group than in the H antigen positive group. It is concluded that the disappearance of A or B antigen may correlate with the invasiveness of the cancerous lesion, while that of the H antigen may reflect the grade of dedifferentiation of the neoplasia with the implication of an unfavorable prognosis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3908586

Source DB:  PubMed          Journal:  Nihon Sanka Fujinka Gakkai Zasshi        ISSN: 0300-9165


  1 in total

1.  Expression of blood group-related antigens in neoplastic uterine cervix.

Authors:  Cecilia Guzmán-Bistoni; Bene Pinillos; M Carmen Blanco-Arias; Asmiria Arenas de Sotolongo; Julia Molina; Jorge García-Tamayo; Eduardo Blasco-Olaetxea
Journal:  Clin Transl Oncol       Date:  2008-04       Impact factor: 3.405

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.